Ferring Email Format
Pharmaceutical Manufacturing
・
5,001-10,000 employees
・
St-Prex, Switzerland
Ferring is a privately owned specialty biopharmaceutical company focused on reproductive medicine, maternal health, gastroenterology, and urology, operating in over 100 countries worldwide.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@ferring.com
Company Overview
Industry
Pharmaceutical Manufacturing
Founded
1950
Headquarters
St-Prex, Switzerland
Revenue
$2.5B-$5B
FUNDING Stage
Private
Website
Key Executives
Jean-Frédéric Paulsen (Chairman and Chief Executive Officer), Dominic Moorhead (Executive Vice President and Chief Financial Officer), Cyril Grandchamp-Desraux (Executive Vice President and Chief Operations Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Ferring?
Ferring uses the first.last format, so Jane Smith would be jane.smith@ferring.com.
What are Ferring's main therapeutic areas?
Ferring focuses on reproductive medicine and maternal health, urology and uro-oncology, and gastroenterology including microbiome therapeutics, along with specialty areas in orthopaedics and endocrinology.
How does Adstiladrin fit into Ferring's uro-oncology portfolio?
Adstiladrin is the first and only FDA-approved non-replicating intravesical gene therapy for adults with high-risk non-muscle invasive bladder cancer, making it a cornerstone of Ferring's uro-oncology commercial portfolio alongside ongoing real-world studies in the U.S.
Where is Ferring headquartered and how many employees does it have?
Ferring is headquartered in Saint-Prex, Switzerland, and employs approximately 6,225 people across operations on six continents. You can use Clay to enrich and verify contact details for specific Ferring offices or teams when building a prospect list.
Who leads Ferring's reproductive medicine pipeline research and development?
Ferring's reproductive medicine pipeline, which includes Rekovelle for infertility and ongoing trials such as the ADAM and ADAPT studies, is overseen by the broader R&D organization under the executive leadership of CEO Jean-Frederic Paulsen and COO Cyril Grandchamp-Desraux.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating